Everolimus, an mTOR inhibitor, has received approval for the treatment of subependymal giant cell astrocytoma (SEGA), and is being investigated in combination with other drugs such as temozolomide, lenvatinib (a VEGFR inhibitor), sorafenib, ribociclib (a CDK inhibitor), and dasatinib (a BCR/ABL and SRC inhibitor). Here, KDR is linked to subependymal giant cell astrocytoma.